Corton Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Corton Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$417K	Sell	18,427 -2,584	-12%	-$60.3K	1.03%	4
2025 Q2	$364K	Buy	+21,011	New	+$389K	0.42%	43
2025 Q1	–	Sell	-7,595	Closed	-$242K	–	184
2024 Q4	$242K	Sell	7,595 -636	-8%	-$19.1K	0.14%	194
2024 Q3	$237K	Sell	8,231 -5,325	-39%	-$197K	0.12%	291
2024 Q2	$520K	Buy	+13,556	New	+$614K	0.27%	43
2023 Q4	–	Sell	-6,083	Closed	-$231K	–	570
2023 Q3	$231K	Buy	+6,083	New	+$267K	0.12%	269
2022 Q3	–	Sell	-5,606	Closed	-$254K	–	276
2022 Q2	$254K	Buy	+5,606	New	+$256K	0.24%	176

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Corton Capital's APLS Position: Q3 2025 in Review

Corton Capital reduced its Apellis Pharmaceuticals (APLS) stake by 12% in Q3 2025, selling an estimated $60.3K and leaving 18,427 shares worth $417K. The position accounts for 1.03% of the portfolio, ranked #4.

Corton Capital first reported a position in APLS in Q2 2022 and has held it in 7 quarters since. The position peaked at $520K in Q2 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

Corton Capital held 18,427 shares of Apellis Pharmaceuticals worth $417K as of Q3 2025.
Corton Capital sold 2,584 Apellis Pharmaceuticals shares in Q3 2025, an estimated $60.3K.
Apellis Pharmaceuticals made up 1.03% of Corton Capital's portfolio in Q3 2025, its #4 holding.
Corton Capital first reported a position in Apellis Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
Corton Capital's Apellis Pharmaceuticals position peaked at $520K in Q2 2024.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.